Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD

J Hepatol. 2024 Feb;80(2):e51-e52. doi: 10.1016/j.jhep.2023.07.017. Epub 2023 Aug 3.

Authors

Vlad Ratziu¹, Jérôme Boursier²; AFEF Group for the Study of Liver Fibrosis

Collaborators

AFEF Group for the Study of Liver Fibrosis:
Victor de Ledinghen, Rodolphe Anty, Charlotte Costentin, Christophe Bureau

Affiliations

¹ Sorbonne Université, Institute of Cardiometabolism and Nutrition, Hospital Pitié Salpêtrière, Paris, France. Electronic address: vlad.ratziu@inserm.fr.
² Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, HIFIH Laboratory, SFR ICAT 4208, Angers University, Angers, France.

PMID: 37543307
DOI: 10.1016/j.jhep.2023.07.017

No abstract available

Publication types

Letter

MeSH terms

Humans
Non-alcoholic Fatty Liver Disease* / diagnosis